GLP‑1 therapies have rapidly evolved from a clinical breakthrough into one of the most material cost and strategy challenges facing health plans. What began as a diabetes treatment and later expanded into obesity has become a defining example of how high-cost drug economics are shifting across the system. While these therapies are not always classified as specialty drugs and unit costs are declining, the potential for widespread, long-term utilization is creating meaningful financial exposure across pharmacy benefits.
